COVID-19 remains a serious threat to the public health worldwide. The world requires effective COVID-19 vaccines/therapeutics for life to 'return to normal'. Vaccine companies are investing huge efforts to design the right strategy to maximize the vaccine efficacy. One key evaluation is the effectiveness of neutralizing antibody (NAb) response, which by itself is no easy job. The conventional Virus Neutralization Test (cVNT) is the ‘gold standard’ for Nab detection but requires handling live SARS-CoV-2 in a specialized biosafety level 3 (BSL3) laboratory. Establish safe and convenient assays are thus urgently needed.

GenScript established a robust pseudovirus-based neutralization assay (pVNT), which can be adopted in BSL2 laboratory. More recently, GenScript also launched a Surrogate Virus Neutralization Test (sVNT) Kit that detects neutralizing antibodies in an hour and allow high throughput. This breakthrough sVNT technology is well received by vaccine community thanks to the benefits: 1) excellent correlation with cVNT and pVNT 2) easiest, fastest, most scalable 3) compatible with variety of animal models.

In this webinar, you will learn:
1. How sVNT and pVNT help to accelerate vaccine research
2. Performance of sVNT and pVNT versus cVNT
3. Selected case studies of sVNT and pVNT in Drug/Vaccine Development

свернуть